Tracking Thinking and Memory After CAR-T Therapy in Multiple Myeloma
Follows changes in thinking and memory in adults with multiple myeloma after CAR-T therapy.
Plain-language title generated from the registry record
Registry title: Neurocognitive Trajectories After BCMA CAR-T
Key facts
- Where
- Charlotte, United StatesSee the site
Where in United States
- Atrium Health Levine CancerCharlotte, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Wake Forest University Health Sciences
- Trial code
- NCT07740317
- Record updated
- 23 October 2026
- Original description
The purpose of this research study is to evaluate cognitive changes over time in participants with relapsed or refractory multiple myeloma who have received chimeric antigen receptor T-cell therapy (CAR-T).Read full original descriptionShow less
Longitudinal Neurocognitive Trajectories After BCMA CAR-T in Multiple Myeloma
The purpose of this research study is to evaluate cognitive changes over time in participants with relapsed or refractory multiple myeloma who have received chimeric antigen receptor T-cell therapy (CAR-T).
Inclusion: Ability to understand and willingness to sign an IRB-approved informed consent; Ability to retain independent decision-making capacity as per the enrolling investigator; Age ≥ 18 years of age at the time of consent; Scheduled to receive BCMA CAR-T therapy for RRMM as confirmed by the treating clinician; Ability to read and understand the English language; ECOG 0-2; If actively taking benzodiazepine, must be able to hold for 3 hours prior to study assessments as per treating clinician; Reliable access to internet access; a tablet, laptop and/or desktop computer with a camera; or willingness to come into the clinic to conduct study procedures as outlined in the Study Calendar- as per participant self-report; Ability to complete required assessments, as determined by the treating clinician.
Exclusion: Concurrent investigational neuroactive drugs; Active central nervous system (CNS) disease; Known neurodegenerative disease or major neurocognitive disorder; Stroke and/or traumatic brain injury (TBI) within 12 months.